

Our Ref: 211  
February 2024

## Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta)
  - Cabozantinib (Cometriq)
  - Nivolumab (Opdivo)
  - Nivolumab + Cabozantinib (Opdivo + Cometriq)
  - Nivolumab + Ipilimumab (Opdivo + Yervoy)
  - Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)
- 
- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**